Effect of brodalumab on patient-reported outcomes in mild, moderate, and severe psoriasis

Font Size

This real-world study sought to investigate the impact of brodalumab on patient-reported outcomes (PROs) across different psoriasis severity levels.

See All

Key take away

Brodalumab (210 mg) rapidly and sustainably achieves high skin clearance rates, significantly improves quality of life, and delivers strong patient-perceived benefits, regardless of baseline psoriasis severity.

Background

This real-world study sought to investigate the impact of brodalumab on patient-reported outcomes (PROs) across different psoriasis severity levels.

Method

The LIBERO study was a prospective, non-interventional trial evaluating brodalumab (210 mg) in adults with plaque psoriasis over 12 and 52 weeks. Psoriasis severity was categorized by the Psoriasis Area Severity Index (PASI) as mild (<10), moderate (10–19), or severe (≥20). The study determined both short- and long-term effects on PROs.

Result

Data from 200 patients with severe psoriasis (31.3%), 263 with moderate disease (41.2%), and 168 with mild disease (26.3%) were analyzed. Across all severity groups, the mean PASI scores dropped rapidly from week 2 and remained low throughout the study. At the end of follow-up, 76.7%, 84.9%, and 82.0% of patients in the mild, moderate, and severe groups, respectively, rated their skin as clear or almost clear.

The mean Dermatology Life Quality Index (DLQI) improved from 11.2, 14.3, and 17.1 to 3.2, 2.9, and 3.8 in these groups. Overall, 73.7% of participants considered brodalumab “quite” or “very” beneficial (Patient Benefit Index) and expressed high satisfaction (Treatment Satisfaction Questionnaire for Medication - 9 items [TSQM-9]). Regaining disease control and minimizing physical impairment yielded the highest Patient Benefit Index scores.

Conclusion

The use of brodalumab (interleukin-17 receptor A antagonist) provided rapid and sustained skin clearance, boosted quality of life, and delivered meaningful patient-perceived benefits, irrespective of baseline psoriasis severity.